A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Inclusion Criteria:

- Histologically confirmed fallopian tube, ovarian epithelial, or primary peritoneal
carcinoma

- Stage II-IV disease

- The following epithelial cell types are allowed:

- Carcinosarcoma

- Serous adenocarcinoma

- Endometrioid adenocarcinoma

- Mucinous adenocarcinoma

- Undifferentiated carcinoma

- Clear cell adenocarcinoma

- Mixed epithelial carcinoma

- Transitional cell carcinoma

- Malignant Brenner's tumor

- Adenocarcinoma not otherwise specified

- Must have undergone prior surgery for ovarian or peritoneal carcinoma within the past
12 weeks

- Optimal (≤ 1 cm residual disease) or suboptimal residual disease following
initial surgery

- Must have a procedure for determining diagnosis of ovarian/peritoneal carcinoma
with appropriate tissue for histologic evaluation

- Synchronous primary endometrial cancer or prior endometrial cancer allowed provided
the following criteria are met:

- Stage ≤ IB

- Less than 3 mm invasion without vascular or lymphatic invasion

- No poorly differentiated subtypes (e.g., grade 3, clear cell, or papillary
serous)

- No epithelial ovarian carcinoma of low malignant potential (borderline carcinomas)

- No CNS disease (e.g., seizures not controlled with standard medical therapy) or
metastasis

- GOG performance status 0-2

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- INR ≤ 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable
dose of therapeutic warfarin for management of venous thrombosis including pulmonary
thrombo-embolus) (applies to part C only)

- PTT < 1.2 times the upper limit of normal (applies to part C only)

- SGOT ≤ 2.5 times normal

- Alkaline phosphatase ≤ 2.5 times normal

- Bilirubin ≤ 1.5 times normal

- Creatinine ≤ 1.5 times normal

- No active bleeding

- Abnormal cardiac conduction (e.g., bundle branch block or heart block) allowed
provided disease has remained stable for the past 6 months

- No unstable angina or myocardial infarction within the past 6 months

- No neuropathy (sensory and motor) > CTCAE grade 1

- Not pregnant or nursing

- Fertile patients must use effective contraception during and for at least 6 months
after completion of study therapy

- No septicemia, severe infection, or acute hepatitis

- No other invasive malignancy within the past 5 years except non-melanoma skin cancer
or localized breast cancer

- No circumstance that would preclude study participation

- No history of allergic reaction to polysorbate 80 (e.g., etoposide or vitamin E)

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human or humanized antibodies (applies to part C only)

- No clinically significant proteinuria

- Must have urine protein-creatinine ratio (UPCR) < 1

- No serious, non-healing wound, ulcer, or bone fracture (applies to part C only)

- At least 3-6 months since prior abdominal fistula or gastrointestinal perforation and
fully recovered (part C only)

- No history of intra-abdominal abscess within the past 28 days (applies to part C
only)

- No active bleeding or pathologic conditions that carry high risk of bleeding, such as
known bleeding disorder, coagulopathy, or tumor involving major vessels (applies to
part C only)

- No history or evidence (upon physical examination) of CNS disease, including primary
brain tumor, seizures not controlled with standard medical therapy, or brain
metastases (applies to part C only)

- No history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA)
or subarachnoid hemorrhage within six months of the first date of treatment on this
study (applies to part C only)

- No significant traumatic injury within 28 days (applies to part C only)

- No clinically significant cardiovascular disease, including any of the following
(applies to part C only):

- Uncontrolled hypertension, defined as systolic BP > 150 mm Hg or diastolic BP >
90 mm Hg

- Myocardial infarction or unstable angina < 6 months prior to registration

- New York Heart Association (NYHA) Grade II or greater congestive heart failure

- Serious cardiac arrhythmia requiring medication

- CTCAE Grade 2 or greater peripheral vascular disease (at least brief (< 24 hrs)
episodes of ischemia managed non-surgically and without permanent deficit)

- History of CVA within the past six months

- No clinical symptoms or signs of gastrointestinal obstruction and who require
parenteral hydration and/or nutrition (applies to part C only)

- No prior therapy with any anti-VEGF drug, including bevacizumab (applies to part C
only)

- No prior chemotherapy

- Prior adjuvant chemotherapy for localized breast cancer allowed provided the
therapy was completed at least 3 years before registration to study and the
patient remains free of recurrent or metastatic disease

- No prior radiotherapy

- No prior cancer therapy that would contraindicate study treatment

- No anticipation of invasive procedures, including any of the following (applies to
part C only):

- Major surgical procedure or open biopsy within 28 days prior to the first date
of bevacizumab therapy (cycle 2)

- Major surgical procedure anticipated during the course of the study

- Core biopsy within 7 days prior to the first date of bevacizumab therapy